Amneal Pharmaceuticals, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AMRX research report →
Range $20 – $27
Price Chart
About the company
Amneal Pharmaceuticals, Inc. , operating alongside its various subsidiaries, is a diversified pharmaceutical company involved in the development, acquisition of licenses, manufacturing, marketing, and distribution of both generic and specialized medicinal products. These offerings span a multitude of delivery formats and target a wide range of therapeutic needs.
- CEO
- Chirag K. Patel
- IPO
- 2018
- Employees
- 8,700
- HQ
- Bridgewater, NJ, US
Get TickerSpark's AI analysis on AMRX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $7.36B
- P/E
- 49.74
- Fwd P/E
- 19.93
- PEG
- 0.02
- P/S
- 2.33
- P/B
- 13.52
- EV/EBITDA
- 15.84
- Div Yield
- 0.00%
- Gross Margin
- 40.24%
- Op Margin
- 15.61%
- Net Margin
- 4.62%
- ROE
- 131.71%
- ROIC
- 10.79%
Latest fiscal year · YoY change
- Revenue
- $3.02B+8.0%
- Gross Profit
- $1.14B+11.3%
- Op Income
- $423.09M
- Net Income
- $72.06M+161.6%
- EPS
- $0.23+160.5%
- OCF Growth
- +15.2%
- FCF Growth
- +22.6%
- 52W High
- $22.13
- 52W Low
- $11.50
- 50D MA
- $20.05
- 200D MA
- $16.25
- Beta
- 1.21
- RSI (14)
- 54
- Avg Volume
- 3.16M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Amneal posted strong Q3 growth, raised 2026 guidance, and said biosimilars, specialty, and complex generics are setting up continued momentum into 2027 and beyond.· November 3, 2026
- Q3 revenue was $863 million, up 10%; adjusted EBITDA was $207 million, up 30%; adjusted EPS was $0.26, up 53%.
- Management raised full-year 2026 guidance across revenue, EBITDA, and EPS, while lowering operating cash flow due to inventory build and collection timing.
- Affordable medicines led growth with $547 million of revenue, up 19%, helped by women's health patches, new launches, and a biosimilar customer order.
- Specialty continued to ramp, with CREXONT and BREKIYA both described as ahead of expectations and gaining share or traction.
- The Kashiv acquisition closed in Q3 and management framed it as a key step in building an end-to-end biosimilars platform with more upside ahead.
Amneal reported Q3 revenue of $863 million, up 10% year over year, adjusted EBITDA of $207 million, up 30%, and adjusted EPS of $0.26, up 53%. Q3 adjusted gross margin was 43.2%, up 50 basis points year over year, and year-to-date revenues were up 8%, adjusted EBITDA up 20%, and adjusted EPS up 34%. By segment, affordable medicines revenue was $547 million, up 19%; specialty revenue was $150 million, up 20%; and AvKARE revenue was $165 million, down 17% as expected due to a difficult comparison. For 2026, Amneal raised guidance to revenue of $3.15 billion to $3.25 billion, adjusted EBITDA of $800 million to $815 million, adjusted EPS of $1.04 to $1.08, and operating cash flow of $325 million to $375 million; the cash flow outlook was reduced by $25 million at the midpoint due to higher finished goods inventory and timing of collections.
Chirag Patel said Amneal is now a more diversified company with multiple growth engines, especially in biosimilars, complex generics, specialty, and GLP-1 manufacturing. He emphasized that the Kashiv transaction gives Amneal end-to-end biosimilar capabilities and that the company is still early in realizing its full potential. His tone was confident and forward-looking, repeatedly pointing to 2027 and beyond as the next leg of growth.
Tasos Konidaris focused on the strength of the quarter and the raised outlook, highlighting the 10% revenue increase, 30% EBITDA growth, and 53% EPS growth. He said Q3 gross margin was 43.2%, up 50 basis points, and noted the full-year 2026 revenue guide midpoint rose by $50 million, EBITDA by $43 million, and EPS by $0.05. He also said operating cash flow guidance moved down by $25 million at the midpoint because Amneal is building internal finished goods inventory to meet demand and some collections shifted into Q1 2027. On leverage, he said net leverage was 3.0x at quarter-end, expects 3.6x by year-end 2026, and still sees debt below 3x by 2028; he also reiterated $400 million to $500 million in expected Kashiv-related financial benefits and said Amneal secured $60 million in New Jersey tax credits.
Analysts pressed for more detail on lanreotide, including Q3 revenue, initial stocking versus patient demand, and the timeline for 60 mg and 90 mg strengths. Management said Q3 lanreotide revenue was about $7 million, expects multiples of that in Q4, and is targeting 30% to 40% market share; it also said the 60 mg and 90 mg strengths will be filed this quarter with a launch expected in the second half of next year. Questions on XOLAIR centered on launch timing and competition; management said it expects to launch in the second half of next year, is in active patent-settlement discussions, and expects to be the second entrant. On CREXONT and BREKIYA, management said prescriber growth and conversions are strong, with CREXONT adding about 400 prescribers per month and BREKIYA likely to nearly double this year and again next year.
The call highlighted multiple visible growth drivers at once: biosimilars with Kashiv integration, a strong complex generics launch cycle, and specialty brands that are still ramping. Management sounded increasingly confident that 2027 and beyond can build on 2026 momentum, especially as lanreotide, XOLAIR, iohexol, and future biosimilar launches expand the portfolio.
Near-term cash flow is pressured by inventory build and delayed collections, and leverage is expected to rise to 3.6x by year-end 2026 before improving later. Several upside opportunities still depend on timing, approvals, and patent/settlement outcomes, including XOLAIR, lanreotide strengths, and European launches, so execution risk remains meaningful.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 45.0%
- Shares Outstanding
- 348.41M
- Float Shares
- 156.70M
of shares held by institutions
315 13F filers
Buy/sell ratio 0.50. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for AMRX, newest first.
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 26.88M | ▲ 315.10K |
| Vanguard Group Inc | 17.91M | ▼ 47.16K |
| Vanguard Portfolio Management LLC | 12.37M | ▲ 227.94K |
| Tpg Gp A, LLC | 12.33M | 0 |
| Rubric Capital Management LP | 8.54M | ▼ 1.63M |
| Vanguard Capital Management LLC | 7.99M | ▲ 277.54K |
| State Street Corp | 7.47M | ▲ 114.06K |
| Citadel Advisors LLC | 6.99M | ▲ 5.87M |
| Invesco Ltd. | 5.97M | ▲ 2.46M |
| Dimensional Fund Advisors LP | 5.82M | ▲ 21.86K |
| Geode Capital Management, LLC | 4.57M | ▼ 570.55K |
| Morgan Stanley | 4.27M | ▲ 160.13K |
Held by 423 ETFs
Biggest fund positions in AMRX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 17, 26 | BUCHI J KEVIN | other | 20,445 |
| Sep 11, 26 | BUCHI J KEVIN | other | 20,445 |
| Sep 11, 26 | BUCHI J KEVIN | other | 20,445 |
| Sep 1, 26 | BOYER ANDREW S | other | 80,000 |
| Aug 21, 26 | BOYER ANDREW S | other | 152,426 |
| Aug 13, 26 | Kiely John | sell | 50,000 |
| Aug 13, 26 | Kiely John | other | 10,000 |
| Aug 12, 26 | Shah Nikita | sell | 146,403 |
| Aug 11, 26 | Daly Jason B. | sell | 6,613 |
| Aug 12, 26 | Daly Jason B. | sell | 210,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our AMRX coverage
Recent articles, reports, and earnings notes.
No research on AMRX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate AMRX report →Amneal Announces European Approval of Adcomfo® (Omalizumab), a Biosimilar to XOLAIR®
globenewswire.com · Nov 17
Amneal: Buy More After Impressive Q3 Results, As Active Drug Pipeline Keeps Growing
seekingalpha.com · Nov 17
Amneal Named BioSpace 2027 Best Place to Work, Ranking No.1 Among Large Employers
globenewswire.com · Nov 10
AMRX Q3 Earnings & Sales Beat Estimates, FY'26 Guidance Raised
zacks.com · Nov 4
Amneal Pharmaceuticals, Inc. (AMRX) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 3
What Amneal Pharmaceuticals (AMRX) Said on Its Q3 Earnings Call
marketbeat.com · Nov 3
Amneal (AMRX) Reports Q3 Earnings: What Key Metrics Have to Say
zacks.com · Nov 3
Amneal Pharmaceuticals (AMRX) Q3 Earnings and Revenues Top Estimates
zacks.com · Nov 3
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.